Product
Apatinib
Aliases
Apatinib Mesylate, Apatinib Mesylate Tablets, Rivoceranib, YN968D1
60 clinical trials
57 indications
Indication
Hepatocellular CarcinomaIndication
cancerIndication
HepatocellularIndication
Stomach CancerIndication
Gastric Esophageal CancerIndication
Small Cell Lung CancerIndication
Non-Small Cell LungIndication
CancerIndication
Advanced Solid TumorIndication
Liver cancerIndication
CholangiocarcinomaIndication
Breast CancerIndication
Triple-Negative Breast CancerIndication
Digestive System CancersIndication
Breast Cancer Brain MetastasesIndication
Esophageal Squamous Cell CarcinomaIndication
Oral CancerIndication
VEGFR2 inhibitorIndication
Programmed Cell Death 1 InhibitorIndication
inductive therapyIndication
Ovarian CancerIndication
Relapsed Ovarian CancerIndication
Breast Cancer MetastaticIndication
Colorectal CancerIndication
ChemotherapyIndication
AngiogenesisIndication
Triple-negative Breast CancerIndication
OsteosarcomaIndication
Pulmonary MetastasesIndication
ApatinibIndication
SarcomaIndication
Oral Squamous Cell CarcinomaIndication
Neoadjuvant TherapyIndication
PD-1Indication
anti-VEGFRIndication
HR+/HER2- Breast CancerIndication
NeuroblastomaIndication
NSCLCIndication
Lung CancerIndication
Esophageal squamous cell carcinomaIndication
efficacyIndication
ToxicityIndication
Nasopharyngeal CarcinomaIndication
Nasopharyngeal NeoplasmsIndication
Recurrent Atypical/Malignant MeningiomaIndication
Recurrent Cervical CarcinomaIndication
cervical cancerIndication
Thyroid CancerIndication
GISTIndication
Biliary Tract MalignanciesIndication
HR+/HER2-negative breast cancerIndication
Esophageal cancerIndication
Small Cell Lung Cancer, Limited StageIndication
Gastric CancerClinical trial
A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic TherapyStatus: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Completed, Estimated PCD: 2020-11-25
Clinical trial
A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell LungStatus: Completed, Estimated PCD: 2022-04-22
Clinical trial
Anti-PD-1 Antibody SHR-1210 Combined With Anti-angiogenesis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard TherapyStatus: Completed, Estimated PCD: 2021-08-04
Clinical trial
An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic CancerStatus: Completed, Estimated PCD: 2020-10-28
Clinical trial
A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate in Advanced Solid Tumor SubjectsStatus: Completed, Estimated PCD: 2021-05-20
Clinical trial
Randomized, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaStatus: Completed, Estimated PCD: 2013-07-01
Clinical trial
A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver Cancer（PLC）or Biliary Tract Carcinoma (BTC)Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer.Status: Terminated, Estimated PCD: 2023-04-14
Clinical trial
A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on Transporter Pgp Substrate Digoxin in Advanced Solid Tumor SubjectsStatus: Completed, Estimated PCD: 2021-04-03
Clinical trial
A Phase II Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib or Apatinib for Microsatellite Instability-High Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With ChemotherapyStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Study of Paclitaxel (Albumin-bound) Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy ProgressionStatus: Recruiting, Estimated PCD: 2026-05-19
Clinical trial
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I TrialStatus: Completed, Estimated PCD: 2020-11-02
Clinical trial
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2031-03-01
Clinical trial
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical StudyStatus: Withdrawn, Estimated PCD: 2020-02-01
Clinical trial
Clinical Study of Fluzopalil Combined With Apatinib for Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Fluzoparib Combined With Apatinib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Phase II Single-arm, Open Label, Multicenter TrialStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
Apatinib in Combination With CDK4/6 Inhibitor and Endocrine Therapy as the First-line Therapy for HR+/ HER2-Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Disitamab Vedotin Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer With HER2 Overexpression: a Prospective, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal CancerStatus: Withdrawn, Estimated PCD: 2022-12-01
Clinical trial
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-01-10
Clinical trial
TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical TrialsStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of OsteosarcomaStatus: Active (not recruiting), Estimated PCD: 2023-11-15
Clinical trial
A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-02-25
Clinical trial
Neoadjuvant Personalized Anti-PD-1 Therapy With Combination of Anti-VEGFR Therapy in Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Randomized Controlled Phase II TrialStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Study of Efficacy of Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Advanced Breast Cancer (Open, Randomized, Phase III)Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: Multi-center, Single-arm, Phase II Clinical Study.Status: Recruiting, Estimated PCD: 2025-12-26
Clinical trial
A Phase II Study of Efficacy and Safety of Combination of Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, TrialStatus: Active (not recruiting), Estimated PCD: 2023-03-29
Clinical trial
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical TrialStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma With Portal Vein Invasion: a Randomized, Open-label, Multicentre TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2022-07-22
Clinical trial
Surgical Conversion of Candonilimab (AK104) Combined With Paclitaxel, S-1 and Apatinib for Unresectable Advanced Gastric(G)/Gastroesophageal Junction(GEJ) CancerStatus: Recruiting, Estimated PCD: 2025-03-21
Clinical trial
A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical StudyStatus: Withdrawn, Estimated PCD: 2020-07-30
Clinical trial
A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal CarcinomaStatus: Completed, Estimated PCD: 2020-04-01
Clinical trial
Clinical Study of Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in AdultsStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Single-arm Phase II Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Advanced Intrahepatic CholangiocarcinomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II StudyStatus: Completed, Estimated PCD: 2020-04-30
Clinical trial
An Open-labeled, Single-arm, Investigator-initiated Phase II Trial of Camrelizumab (Anti-PD-1 Antibody) in Combination With Apatinib and Eribulin in Patients With Advanced Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-11-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2020-03-25
Clinical trial
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical StudyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal CancerStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract MalignanciesStatus: Recruiting, Estimated PCD: 2029-02-23
Clinical trial
Antiangiogenic Therapy or Chemotherapy Combined With PD-1 Inhibitor Versus Standard Chemotherapy for PD-1 Inhibitor Refractory R/M NPCStatus: Recruiting, Estimated PCD: 2023-09-20
Clinical trial
Efficacy and Safety of Apatinib Mesylate in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma After the Failure of Conventional Treatment: a Phase II Clinical TrialStatus: Completed, Estimated PCD: 2019-12-01
Clinical trial
A Randomized, Controlled, Open-label, Phase III Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Based on SNF Molecular ClassificationStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Patients Failed in First-line Chemotherapy: A Phase II StudyStatus: Terminated, Estimated PCD: 2021-04-25
Clinical trial
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled TrialStatus: , Estimated PCD: 2025-12-31
Clinical trial
A Single Arm, Exploratory Clinical Study on the Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAICStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Double-arm, Non-randomized Controlled, Open-label Clinical Study of Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line Esophageal Squamous Cell Carcinoma.Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Adebrelimab Plus Apatinib for Maintenance Treatment of Extensive Small Cell Lung Cancer After First-line Induction With Adebrelimab Plus Chemotherapy: a Prospective, Single-arm, Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single-arm, Prospective, Exploratory Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-07-01